ElizabethKatherineLeeMD

Oncology • Boston, MA

Gynecologic Cancer

Instructor, Medical Gynecologic Oncology

Join to view full profile

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lee's full profile

Already have an account?

Office
450 Brookline Ave
# Dana-Far
Boston, MA 02215
Phone+1 617-632-6094

Fax+1 617-632-3479

Education & Training

Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2017 - 2020
Johns Hopkins UniversityResidency, Internal Medicine, 2014 - 2017
University of Pittsburgh School of MedicineClass of 2014

Certifications & Licensure

MA State Medical License 2017 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

18 citations
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Timothy A Yap, Elisa Fontana, Elizabeth K Lee, David R Spigel, Martin Højgaard
Nature Medicine. 2023-06-01
121 citations
Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial.
Panagiotis A. Konstantinopoulos, Su Chun Cheng, Andrea E. Wahner Hendrickson, Richard T. Penson, Susan Schumer
The Lancet. Oncology. 2020-06-15
34 citations
A Replication stress biomarker is associated with response to gemcitabine versus combined gemcitabine and ATR inhibitor therapy in ovarian cancer
Panagiotis A. Konstantinopoulos, Alexandre André B.A. da Costa, Doga Gulhan, Elizabeth K. Lee, Su Chun Cheng
Nature Communications. 2021-09-22

Journal Articles

POLE-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure.
Lee EK, Lindeman NI, Matulonis UA, Konstantinopoulos PA, Gynecologic Oncology Reports, 5/2019

Press Mentions

Investigational Rinatabart Sesutecan (Rina-S) Shows Promising Anti-Tumor Activity as Single Agent in Heavily Pretreated Patients with Ovarian and Endometrial Cancers in Phase 1/2 Clinical TrialSeptember 15th, 2024
Comprehensive cancer research from Dana-Farber to lead ESMO Congress 2024September 11th, 2024

Professional Memberships